Successful use of therapeutic anticoagulation therapy in two patients with moderate stroke from the second day of onset: A case report and literature review.

Anticoagulants Atrial fibrillation Ischemic stroke Stroke Warfarin

Journal

Annals of medicine and surgery (2012)
ISSN: 2049-0801
Titre abrégé: Ann Med Surg (Lond)
Pays: England
ID NLM: 101616869

Informations de publication

Date de publication:
Oct 2022
Historique:
received: 15 08 2022
revised: 11 09 2022
accepted: 11 09 2022
entrez: 21 10 2022
pubmed: 22 10 2022
medline: 22 10 2022
Statut: epublish

Résumé

Hemorrhagic transformation of ischemic stroke is one of the most traumatic consequences of ischemic stroke. Therefore, deciding the optimal time for anticoagulant application and its effect on clinical outcome, recurrence and risk for hemorrhagic transformation are still in quarry. The European Heart Rhythm Association recommends the usage of anticoagulants after 3-4 days after a mild stroke, 6 days after moderate stroke and 12 days after a severe stroke. In our case report, we present two patients who started full therapeutic anticoagulation of low molecular weight heparin from the first day after moderate ischemic stroke, warfarin was added later guided by INR and discharged on oral anticoagulants for associated AF. They improved clinically with improved motor function for both upper and lower limbs, sensation and gaze without any complication followed by serial CT. As a result of this case report, clinical improvement has not been associated with hemorrhagic sequelae of anticoagulant administration on the first day. At this point, we recommend conducting a trial to study the effect of early application of anticoagulants from the first day on clinical outcome, recurrence, and hemorrhagic transfusion of stroke.

Identifiants

pubmed: 36268411
doi: 10.1016/j.amsu.2022.104726
pii: S2049-0801(22)01486-8
pmc: PMC9577847
doi:

Types de publication

Case Reports

Langues

eng

Pagination

104726

Informations de copyright

© 2022 The Authors.

Références

Eur J Cardiothorac Surg. 2016 Nov;50(5):e1-e88
pubmed: 27663299
Stroke. 2014 Jul;45(7):2160-236
pubmed: 24788967
J Res Med Sci. 2012 Apr;17(4):396-401
pubmed: 23267405
Drugs R D. 2016 Jun;16(2):149-54
pubmed: 26892845
Stroke. 2004 Apr;35(4):948-51
pubmed: 14988571
Eur Heart J. 2018 Apr 21;39(16):1330-1393
pubmed: 29562325
Pharmacotherapy. 2020 Jan;40(1):55-71
pubmed: 31698510
Chest. 2018 Nov;154(5):1121-1201
pubmed: 30144419
J Stroke Cerebrovasc Dis. 2004 Nov-Dec;13(6):235-46
pubmed: 17903981
Stroke. 2018 Jul;49(7):1762-1765
pubmed: 29844030
Brain Behav. 2020 Jan;10(1):e01497
pubmed: 31846215
Arch Neurol. 2008 Sep;65(9):1169-73
pubmed: 18625852
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
Thromb Haemost. 2016 Aug 30;116(3):410-6
pubmed: 27346426
Stroke. 1991 Aug;22(8):983-8
pubmed: 1866765
Int J Surg. 2020 Dec;84:226-230
pubmed: 33181358
Thromb Haemost. 2017 Dec;117(12):2215-2236
pubmed: 29212110

Auteurs

Mostafa Meshref (M)

Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Nour Shaheen (N)

Faculty of Medicine, Alexandria University, Alexandria, Egypt.

Rehab Adel Diab (RA)

Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Mariam Tarek Desouki (MT)

Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Yara Amro (Y)

Pharmacist Ministry of Health, Cairo, Egypt.

Shiamaa M Khairat (SM)

Division of Neurology Medicine, Department of Internal Medicine, King Khalid Hospital Hail, Saudi Arabia.

Mohamed Ali (M)

Neurology Department, Louisiana State University, Shreveport, LA, USA.

Mahmoud Galal Ahmed (MG)

Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt.

Classifications MeSH